News

Pharma manufacturing 'boom' faces high costs, potential delays
With more than $270 billion in commitments to date, a new wave of pharmaceutical manufacturing is slated to hit the US. At least, that’s what the industry is trying to project.
Notable healthcare headlines for the week: Novo Nordisk, Thermo Fisher and UnitedHealth in focus
Wall Street's major averages plummeted on Friday after Israel and Iran traded missile strikes and stoked concerns of an ...
Eli Lilly Just Made Another Move to Dominate the Weight Loss Market: Should You Buy the Stock?
Eli Lilly made a move that could help address a drawback of its anti-obesity medicines. Lilly's business extends far beyond ...
Developers of new 21-acre mixed-use district near TMC bet on long-term biotech play
Houston’s life sciences real estate market is growing again — this time with a 21.3-acre mixed-use district aimed at biotech ...
Goldman Sachs Remains a Buy on Eli Lilly (LLY) With an $883 Price Target
Eli Lilly and Company (NYSE:LLY) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. Analyst Asad Haider from ...
Jim Cramer on Eli Lilly: “We Like It”
Eli Lilly and Company (NYSE: LLY) is one of the 17 stocks that Jim Cramer commented on. Cramer showed a positive sentiment ...
Lilly’s experimental obesity drug shows promise in early study
An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the ...
NHS patients with Alzheimer's WON'T access 'miracle' drugs as watchdog says they are 'too expensive'
The National Institute for Health and Care Excellence (NICE) has refused the 'miracle' drugs lecanemab and donanemab for use ...
NHS patients battling Alzheimer's WON'T be offered 'miracle' drugs as health watchdog rules they are 'too expensive to justify'
The National Institute for Health and Care Excellence (NICE) has refused the 'miracle' drugs lecanemab and donanemab for use on the NHS as they are too expensive to justify.